Sanbio Inc., of Mountain View, Calif., part of Sanbio Ltd., of Tokyo, appointed Mohammad El-Kalay senior vice president of technical operations. He will be responsible for all technical operations, from process development, production, and supply chain management, to quality control and quality assurance. Read More

Shionogi & Co. Ltd., of Osaka, Japan, said lusutrombopag (S-888711), an investigational, once-daily, orally administered, small-molecule thrombopoietin receptor agonist, demonstrated superiority to placebo and met the primary and all pre-specified important secondary endpoints in a global phase III study (L-PLUS2) in thrombocytopenia in patients with chronic liver disease undergoing non-emergent invasive procedures. Read More

HONG KONG – Singapore startup Enleofen Bio Pte Ltd. has acquired the licensing rights of a breakthrough discovery by the Duke-National University of Singapore (NUS) Medical School and the National Heart Centre Singapore (NHCS) in cardiovascular fibrosis drivers. Read More

A study showing that an inhibitor of WNT signaling had differential effects on the lung and bone metastasis of breast cancer could have important implications for treating breast cancer, Chinese researchers reported in the Sept. 11, 2017, online edition of Nature Cell Biology. Read More

HONG KONG – CSPC Pharmaceutical Group Ltd. received orphan drug status for its mitoxantrone liposome product from the FDA, though the Chinese company warned that much work remains to get the phase II-stage drug across the finish line in the initial U.S. and China markets. Read More

Headlines alleging manipulations of the drug market feed the public perception of big, bad pharma, but they do little to tell the whole story of the challenges of launching a biosimilar. Read More